<code id='880A06F199'></code><style id='880A06F199'></style>
    • <acronym id='880A06F199'></acronym>
      <center id='880A06F199'><center id='880A06F199'><tfoot id='880A06F199'></tfoot></center><abbr id='880A06F199'><dir id='880A06F199'><tfoot id='880A06F199'></tfoot><noframes id='880A06F199'>

    • <optgroup id='880A06F199'><strike id='880A06F199'><sup id='880A06F199'></sup></strike><code id='880A06F199'></code></optgroup>
        1. <b id='880A06F199'><label id='880A06F199'><select id='880A06F199'><dt id='880A06F199'><span id='880A06F199'></span></dt></select></label></b><u id='880A06F199'></u>
          <i id='880A06F199'><strike id='880A06F199'><tt id='880A06F199'><pre id='880A06F199'></pre></tt></strike></i>

          Home / fashion / leisure time

          leisure time


          leisure time

          author:fashion    Page View:7194
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In